Jeff Barno

Jeff Barno, PharmD, MBA, currently serves as a Senior Medical Science Liaison in Rare Disease at Amgen, a role assumed in March 2023. Prior experience includes serving as a Medical Science Liaison for Rare Disease and Pipeline at Alnylam Pharmaceuticals, where work focused on conditions such as Acute Hepatic Porphyria and Primary Hyperoxaluria Type 1. Jeff Barno held various positions at Novo Nordisk from July 2013 to September 2021, including Director of Program Development and Training in Medical Affairs and Senior Medical Liaison, with expertise in NASH, Rare Blood Disorders, and Rare Endocrine Disorders. Early career experience includes a Commercial Team Intern role at Chelsea Therapeutics, contributing to the NDA submission for an orphan drug candidate. Educational credentials include a PharmD (summa cum laude, valedictorian) and an MBA in Healthcare Administration from Wingate University, as well as an undergraduate degree from Binghamton University.